costs by eliminating removal procedures and life-threatening complications such as infections by absorbing and restoring tissue to its natural physiology, while maintaining performance of titanium implants. The approach leverages decades of expertise, strategic partnerships, and presents a unique opportunity for a large exit consisting of multiple commercialized product lines, starting with ortho extremities and maxillofacial fixation. FDA clearance and commercialization are expected for multiple product lines: Maxillofacial Fixation, ortho extremities fixation and sports medicine indications. Exit via acquisition is expected between 2027-29 at a minimum revenue multiple of 20x based upon comparable biomaterial implant acquisitions.